Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Obtains Exclusive Rights to Negotiate TriPath Acquisition

NEW YORK (GenomeWeb News) – Becton Dickinson has exclusive rights to negotiate an acquisition of TriPath Imaging, according to documents filed with the Securities and Exchange Commission yesterday.
As GenomeWeb News reported on Tuesday, Becton Dickinson offered  buy all outstanding TriPath shares for $9.25 each, or about $350 million. The company currently holds a 6.5-percent stake in TriPath.
According to the filing, the exclusive agreement is in place until Aug. 25. If TriPath violates the agreement, it will pay Becton Dickinson $5 million in termination fees.
The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.